Mehmet Şerif CANSEVER, Ertuğrul KIYKIM, Tanyel ZÜBARİOĞLU, Ayşe Ciğdem AKTUĞLU ZEYBEK, Özgür KASAPÇOPUR, Kenan BARUT

Evaluation of plasma carnitine status in patients diagnosed with juvenile idiopathic arthritis

Background/aim: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood and manifests mainly as autoinflammation of the joints and other tissues. Several treatment options such as nonsteroidal antiinflammatory drugs, methotrexate, and intra-articular steroids are widely used to relieve and improve this inflammation. Secondary carnitine deficiency can be detected in chronic diseases by either renal loss or increased demand. While carnitine status can be associated with several conditions, in the present study our aim is to determine the levels of free carnitine and acyl-carnitine in Turkish JIA patients. Materials and methods: One hundred and fourteen patients diagnosed with juvenile idiopathic arthritis and 50 healthy individuals who served as the control group were included in the study. A fasting blood sample was collected from the children in both groups to determine free carnitine and acylcarnitine ester by quadripole electrospray tandem mass spectrometry (ESI-MS/ MS). Results: Screening of acyl-carnitine profile revealed free carnitine, C14, C14:2, C16, C16-OH, and C18 carnitine levels were higher (p < 0.0001, p < 0.0001, p < 0.001, p < 0.001, and p = 0.011, respectively), while C2, C3, C4, C6, C8, C10, C10:1, C10:2, C3DC, C4DC, C5DC, C4-OH, and C18:1-OH carnitine levels were lower (p < 0.0001) in JIA patients in comparison to the control group. Total acylcarnitine levels (p < 0.001) and acyl-carnitine to free carnitine ratio (p < 0.001) were also lower in JIA patients than the control group. Free carnitine levels were significantly higher (48.05 ± 13.36 μmol/L) in patients under antiinflammatory drug therapy than those who did not receive any treatment (43.18 ± 7.96 μmol/L) (p = 0.004). Conclusion: In the present study we were not able to define secondary carnitine deficiency in JIA patients, although free carnitine and acyl-carnitine variations were detected in JIA patients. In conclusion, routine carnitine supplementation is not recommended in all patients with JIA.

PDF

___

1. Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Annals of the Rheumatic Diseases 2010; 69(7):1260-1263. doi: 10.1136/ard.2010.133033
2. Moncrieffe H, Prahalad S, Thompson SD. Genetics of juvenile idiopathic arthritis: new tools bring new approaches. Current Opinion in Rheumatology 2014; 26(5):579-584. doi: 10.1097/ BOR.0000000000000094
3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. The Journal of Rheumatology 2004;31(2):390- 392.
4. Kessler EA, Becker ML. Therapeutic advancements in juvenile idiopathic arthritis. Best Practice & Research: Clinical Rheumatology 2014;28(2):293-313. doi: 10.1016/j. berh.2014.03.005
5. Backström M, Tynjälä P, Ylijoki H, Aalto K, Kärki J et al. Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study. Rheumatology (Oxford) 2016;55(4):615-623. doi: 10.1093/rheumatology/kev353
6. Walter JH. L-Carnitine. Archives of Disease in Childhood 1996;74(6):475-478. doi: 10.1136/adc.74.6.475
7. Stanley CA. Carnitine deficiency disorders in children. Annals of the New York Academy of Sciences 2004; 1033:42-51. doi: 10.1196/annals.1320.004
8. Mescka C, Moraes T, Rosa A, Mazzola P, Piccoli B et al. In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease. Metabolic Brain Disease 2011; 26(1):21-28. doi: 10.1007/s11011-011-9238-x
9. Li JL, Wang QY, Luan HY, Kang ZC, Wang CB. Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. Journal of Biomedical Science 2012; 21;19(1):32. doi: 10.1186/1423-0127-19-32
10. Garcia CL, Filippi S, Mosesso P, Calvani M, Nicolai R, Mosconi L, Palitti F. The protective effect of L-carnitine in peripheral blood human lymphocytes exposed to oxidative agents. Mutagenesis. 2006; 21(1):21-27. doi: 10.1093/mutage/gei065
11. Khalatbari-Soltani S, Tabibi H. Inflammation and L-carnitine therapy in hemodialysis patients: a review. Clinical and Experimental Nephrology 2015; 19(3):331-335. doi: 10.1007/ s10157-014-1061-3
12. Tedgui A. The role of inflammation in atherothrombosis: implications for clinical practice. Vascular Medicine 2005; 10(1): 45-53. doi: 10.1191/1358863x05vn589ra
13. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 21;108(16):1917-1923. doi: 10.1161/01.CIR.0000089190.95415.9F
14. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 2;179(4076):899-902. doi: 10.1126/ science.179.4076.899
15. Roe CR, Millington DS, Kahler SG, Kodo N, Norwood DL. Carnitine homeostasis in the organic acidurias. Progress in clinical and biological research 1990; 321:383-402.
16. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annual Review of Physiology 2002; 64:477-502. doi: 10.1146/annurev.physiol.64.082201.154705
17. Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Critical Care 2005; 5;9(5):431-440. doi: 10.1186/cc3742
18. Holme E, Greter J, Jacobson CE, Lindstedt S, Nordin I et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989; 26;2(8661):469-473. doi: 10.1016/s0140-6736(89)92086-2
19. Veselá E, Racek J, Trefil L, Jankovy’ch V, Pojer M. Effect of L-carnitine supplementation in hemodialysis patients. Nephron 2001; 88(3):218-223. doi: 10.1159/000045993
20. Sakurauchi Y, Matsumoto Y, Shinzato T, Takai I, Nakamura Y et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. American Journal of Kidney Diseases 1998; 32(2):258-264. doi: 10.1053/ajkd.1998. v32.pm9708610
21. Uysal N, Yalaz G, Acikgoz O, Gonenc S, Kayatekin BM. Effect of L-carnitine on diabetogenic action of streptozotocin in rats. Neuro Endocrinology Letters 2005; 26(4): 419-22.
22. Rezaee H, Khalili H, Salamzadeh J, Jafari S, Abdollahi A. Potential benefits of carnitine in HIV-positive patients. Future Virology 2012; 7(1):73-83. Doi: 0.2217/fvl.11.133
23. Bonafé L, Berger MM, Que YA, Mechanick JI. Carnitine deficiency in chronic critical illness. Current Opinion in Clinical Nutrition & Metabolic Care 2014; 17(2):200-209. doi: 10.1097/MCO.0000000000000037
24. Hatamkhani S, Karimzadeh I, Elyasi S, Farsaie S, Khalili H. Carnitine and sepsis: a review of an old clinical dilemma. Journal of Pharmaceutical Sciences 2013; 16(3):414-423. doi: 10.18433/j3js4c
25. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatric Rheumatology Online Journal 2014; 23; 12:13. doi: 10.1186/1546-0096-12-13
26. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003; 111(6 Pt 1):1399-1406. doi: 10.1542/peds.111.6.1399
27. Millington DS, Norwood DL, Kodo N, Roe CR, Inoue F. Application of fast atom bombardment with tandem mass spectrometry and liquid chromatography/mass spectrometry to the analysis of acylcarnitines in human urine, blood, and tissue. Analytical Biochemistry 1989; 1;180(2):331-339. doi: 10.1016/0003-2697(89)90441-7
28. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clinical Pharmacokinetics 2012; 1;51(9):553-572. doi: 10.1007/ BF03261931